AURAAura Biosciences, Inc.
$6.50+13% 1Y
$6.50
$4.9752 weeks$8.90
Price
+13%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 6% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for AURA today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$672.0M
1 year+13%
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 12, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 11, 2026On the Effective Date the Company announced its organizational realignment (the “Realignment”) to streamline its operating plan and organizational structure to focus resources in ocular oncology, including its plan to minimize resource allocation towards its non-muscle invasive bladder cancer (“NMIBC”) program on a …Earnings release · Form 8-K
- Jul 8, 2026Appointment of New Director to the Board of Directors On July 3, 2026, the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) increased the size of the Board from six to seven directors and unanimously appointed Jeremy Bender, Ph.D., M.B.A., as a Class II director, effective July 7, 2026 (the …Director or officer change · Form 8-K
- May 11, 2026On May 11, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts, and others.Earnings release · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.